Background: Cochlin-tomoprotein (CTP) has recently emerged as a promising diagnostic marker for perilymphatic fistula (PLF), but its utility beyond diagnosis remains unclear.
Aims/objectives: We aim to clarify whether CTP levels could help to predict prognosis, treatment efficacy and initial symptoms for PLF.
Material/methods: This retrospective study included 20 patients with acute sensorineural hearing loss who underwent CTP testing.
Results: Among cases of PLF (CTP levels ≥30 ng/mL), higher CTP levels were significantly associated with poorer improvement of hearing. However, the patients with PLF showed better improvement of hearing than those without PLF. When using a level of CTP <25 ng/mL, the surgical intervention group showed better improvement of hearing than the conservative treatment group. The patients presenting progression of hearing loss (≥10 dB) showed significantly higher levels of CTP. Receiver operating characteristic curve analysis revealed that a cut-off level of CTP 26.9 ng/mL predicted hearing improvement ≥15 dB with an AUC of 0.85 (95% CI: 0.68-1.00, p = 0.0335), yielding a sensitivity of 68.8% and a specificity of 100%.
Conclusion: The current proposal of CTP ≥30 ng/mL or nearby levels can be used not only as a diagnostic marker, but also as an indicator for initial symptoms and prognosis.
扫码关注我们
求助内容:
应助结果提醒方式:
